Introduction
Ovarian cancer ranks as the fourth leading cause of cancer related mortality among women in the United States and is the primary cause of death from gynecologic cancers. Approximately one in 70 women will develop ovarian cancer in their lifetime, the majority (460%) initially presenting with intraperitoneal metastases. Unfortunately, these patients have a 10 ± 20% overall survival despite the use of aggressive cytoreductive surgical techniques and combination therapy (Boente et al., 1993) . Identifying somatically acquired genetic changes that alter patient prognosis is a critical step toward gaining a more comprehensive understanding of ovarian cancer biology and improving current diagnostic and therapeutic strategies.
Through comparative genomic hybridization, loss of heterozygosity (LOH) analyses and microcell fusion, several chromosomes have already been implicated in epithelial ovarian cancer as containing tumor suppressor genes important in tumor initiation and/or progression. These include chromosomes 1, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 17, 18, 19, 21, 22 and the X chromosome (Lee et al., 1989 (Lee et al., , 1990 Ehlen and Dubeau, 1990; Li et al., 1991; Sato et al., 1991; Chenevix-Trench et al., 1992 Eccles et al., 1992a,b,c; Gallion et al., 1992 Gallion et al., , 1996 Saito et al., 1992; Cliby et al., 1993; Dodson et al., 1993; Allan et al., 1994; Engle®eld et al., 1994; Rimessi et al., 1994; Risinger et al., 1994; Amfo et al., 1995; Zenklusen et al., 1995; Iwabuchi et al., 1995; Bryan et al., 1996; Cheng et al., 1996; Kerr et al., 1996; Bandera et al., 1997; Edelson et al., 1997; Hatta et al., 1997) . While some of these loci associate with known tumor suppressors such as p53 or BRCA1 on chromosome 17, many of these chromosomes likely contain one or several undiscovered tumor suppressor loci of signi®-cance in ovarian cancer.
The dissection of somatically acquired genetic events important in tumor progression is, however, complicated by several factors. First, tumorigenesis involves the deregulation of numerous and often complex biochemical pathways. Second, tumor cells are often genetically unstable. Identifying those genetic changes which are important in a background of genetic instability can prove to be challenging. Third, intratumor heterogeneity can mask the identi®cation of critical mutational events. Finally, a primary tumor site may contain a mixture of tumorigenic and nontumorigenic cells. When using a purely genomicsbased approach for characterizing ampli®cations and deletions, sucient presence of stromal or other nontumorigenic cells can sometimes confound the interpretation of results.
Microcell-mediated chromosome transfer can bypass many of these complicating factors through functional complementation of the tumorigenic phenotype. The resulting microcell hybrid clones can be tested for changes in anchorage-dependent and independent growth rate, and for tumorigenicity in nude mice. In the past, somatic cell fusion and microcell fusion have proven to be an invaluable tool in de®ning the role of tumor suppressor genes in human cancer, and microcell fusion techniques have already provided evidence for the chromosomal location of several tumor suppressor genes (reviewed in Anderson and Stanbridge, 1993) . Because microcell fusion is based upon phenotypic changes observed in genetically unstable tumor cells, a functional-based approach to gene mapping can often be applied more con®dently than standard genomicsbased approaches toward the identi®cation of tumor suppressor genes.
Several lines of evidence suggest that chromosome 22 harbors an important tumor suppressor gene(s) in ovarian cancer. Various laboratories have now reported greater than 70% LOH on chromosome 22q in ovarian cancer Dodson et al., 1993; Engle®eld et al., 1994; Bryan et al., 1996; Silverman et al., 1997) . Engle®eld et al. (1994) reported 71% LOH on chromosome 22q which was localized distal to D22S283 (22q12-qter). More recently, reports of greater than 80% LOH in ovarian cancer have narrowed the critical region(s) for a putative tumor suppressor gene to chromosome 22q13.3 (Engle®eld et al., 1994; Silverman et al., 1997) . LOH on chromosome 22 also associated with higher grade tumors. Eighty-four per cent of grade 3 tumors exhibited LOH as compared to only 19% of grade 1 tumors, suggesting that loss of chromosome 22 may be associated with late or aggressive disease (Bryan et al., 1996) .
Chromosome 22 allelic loss is also not restricted to epithelial ovarian cancer, or to the 22q13.1 region. Chromosome 22 deletion and LOH have been reported in glioblastomas, meningiomas, schwannomas, rhabdoid tumors, non-small cell lung carcinomas, hepatocellular carcinomas, pheochromocytomas, and colon cancers (Tanaka et al., 1992; Irving et al., 1993; Shin et al., 1993; Takahashi et al., 1993; Shiseki et al., 1994; Akagi et al., 1995; Ng et al., 1995; Papi et al., 1995; Yana et al., 1995; Jacoby et al., 1996; Scho®eld et al., 1996) . In meningioma, homozygous deletions and LOH have identi®ed multiple regions critical for tumor progression including an allelic deletion region within 22q13.3, and the region surrounding the MN1 locus at 22q11 (Dumanski et al., 1990; Cogen et al., 1991; Schneider et al., 1992; Akagi et al., 1995) . In rhabdoid tumors, a potentially distinct tumor suppressor locus has also been localized to chromosome 22q11 (Biegel et al., 1996) . Together these data suggest that LOH on chromosome 22 is an important later genetic event seen in several cancers in which one or more tumor suppressors may play a critical role.
While these data strongly support the presence of a novel tumor suppressor locus (or loci) on chromosome 22, LOH mapping is correlative in nature and works on the assumption that any observation of allelic loss in this 22q region must contribute to tumorigenesis. Furthermore, few if any studies have linked functional changes to the presence or absence of chromosome 22 in tumor cells. We therefore selected microcell-mediated chromosome transfer to provide functional complementation for a missing tumor suppressor locus (loci). In this study, we report that transfer of chromosome 22 into the malignant ovarian cancer cell line SKOv-3 results in a signi®cant reduction in tumor growth potential both in vitro and in vivo.
Results

Microcell fusion
In human tumors where genomic instability is often the hallmark, the identi®cation of clinically important somatic mutations can be a cumbersome task. For this reason, microcell-mediated transfer of chromosome 22 into the SKOv-3 ovarian cancer cell line was used to localize a novel tumor suppressor locus. The SKOv-3 cell line was chosen as the recipient cell line primarily due to its demonstrated tumorigenicity in nude mice and its ability to grow in soft agar. Furthermore, microsatellite analysis of chromosome 22 in SKOv-3 cells revealed large regions of homozygous loss (data not shown) which overlapped with the critical region(s) de®ned by LOH analyses. We also tested the SKOv-3 cell line for relative resistance to the toxic eects of phytohemagglutinin P (PHA-P), for survival in the necessary concentrations of polyethylene glycol (PEG) required for microcell fusion, and for the ability to grow clonogenically.
SKOv-3 clones containing the psv 2 neo-chromosome 22 were initially identi®ed through G418 resistance. Twenty individual microcell hybrid clones were selected. Microsatellite analysis and chromosome painting con®rmed the presence of an additional psv 2 neo-chromosome 22. Two of these microcell hybrids, however, were multinucleate and appeared to be the product of a somatic cell fusion. This hypothesis was con®rmed by G11 banding, and the somatic cell fusion clones were consequently removed from further study. All remaining microcell fusion products were found to be negative for the presence of contaminating mouse DNA by G11 banding (Aldahe et al., 1977) .
Phenotypic characterization of the microcell hybrids
The microcell hybrids were ®rst examined for changes in cell morphology. In general, the microcell hybrids appeared larger,¯atter, and often more rounded in appearance than the SKOv-3 parental cell line. However, the most dramatic in vitro phenotype was the complete extinction of anchorage independent growth in 16 of the 18 microcell hybrids (Figure 1a) . While the parental SKOv-3 cell line was characterized by the formation of large healthy colonies, the microcell hybrid clones were typi®ed by the complete loss of ability to grow under anchorage independent conditions (Figure 1c ). Cell doubling time estimates were also signi®cantly increased among the microcell hybrids ( Figure 1b) . Interestingly, in vitro doubling time estimates completely mirrored soft agar growth results suggesting that chromosome 22 in¯uences SKOv-3 cell growth under both anchorage-dependent and anchorage-independent conditions. Cellular growth in the absence of substrate often predicts tumorigenic behavior. In an eort to evaluate whether psv 2 neo-chromosome 22 microcell transfer results in changes in tumorigenic potential in vivo, nine microcell hybrids and the parental SKOv-3 cell line were subcutaneously injected (unilaterally) into the CD1 nu/nu mouse strain. The predominant result was a dramatic reduction in tumor formation (Figure 2) . Eight of the nine microcell hybrid lines demonstrated substantially increased tumor latency and repressed tumor growth in nude mice (Table 1) .
Furthermore, because no selective pressure was maintained on the microcell hybrid tumor-derived cells while being passaged in the nude mice, we hypothesized that those tumors appearing after an increased latency period may have become functionally revertant by loss of all or part of the psv 2 neochromosome 22. To address this question, after sacri®cing the mice, we removed several latent growing tumors derived from microcell hybrids #01 and #18. The explants were cultured for 2 ± 3 days in the absence of G418 selection and the tumors were then analysed for dierences in anchorage-independent growth in the presence and absence of G418. Revertant colony formation appeared in both of these microcell hybrid tumor reconstitutes, but only in the absence of G418 selection (Figure 3 ). This observation supports the role of chromosome 22 in ovarian cancer tumorigenesis, because not only did microcell fusion of chromosome 22 into SKOv-3 cells result in decreased tumorigenic potential, but reversion to a growth permissive state in soft agar and nude mice associated with loss of G418 resistance.
While these data support the hypothesis that a novel tumor suppressor locus (loci) on chromosome 22 aects SKOv-3 cell growth and tumorigenicity, several alternative possibilities need to be addressed. For example, the changes in growth and/or tumorigenicity of the microcell hybrids may only have been a secondary eect of the microcell fusion process itself. Several pieces of evidence refute this hypothesis. First, the latent tumor formation of hybrids #01 and #18 in nude mice associated with the loss of G418 resistance when these tumor explants were assayed in soft agar (Figure 3) . Second, the microcell fusion procedure done in the absence of microcells at no time produced G418 resistant colonies. Third, the introduction of a YAC containing material from the chromosome 22q13 region failed to alter the tumorigenic potential of the SKOv-3 cells (Figure 4) . Fourth, despite the successful transfer of psv 2 neo-chromosome 22 into microcell hybrid #11, this hybrid more closely resembled the parental SKOv-3 cell line in both anchorage-dependent growth and tumor formation in vivo. Because microcell hybrid #11 behaved more like the parental line while still retaining the psv 2 neochromosome 22, it stands to reason that the changes in tumorigenic potential observed in the remaining microcell hybrids cannot simply be a consequence of the microcell fusion procedure itself.
Alternatively, it could be hypothesized that these phenotypic changes observed among the microcell hybrids could be the result of clonal selection. As a control for genetic heterogeneity within the SKOv-3 cell line, ®ve randomly selected single cell clones from the SKOv-3 parental cell line were isolated and tested for anchorage-independent growth in soft agar. While there wsa large variability in colony formation among the clones, all single cell-derived SKOv-3 clones demonstrated the ability to form colonies in soft agar (Figure 4a ). These data are in direct contrast to the 16 of 18 microcell hybrids that failed to grow in soft agar. The same ®ve clones were next injected subcutaneously into CD1 nu/nu mice. Tumor growth patterns similar to the parental line were observed in all ®ve clones (Figure 4b ), while repression of tumor growth was observed in eight out of nine microcell hybrids (Table 1) . 0/3 no tumor no tumor Hyb#15 37.7+3.3 no colonies (0%) 0/6 no tumor no tumor Hyb#16 37.5+6.2 no colonies (0%) 0/6 no tumor no tumor Hyb#17 32.8+1.6 no colonies (0%) 0/6 no tumor no tumor Hyb#18 40.8+3.8 no colonies (17%) 1/6 53.0+0.0 0.7+1.1 Table summarizing the phenotypic dierences among selected microcell hybrids. In vitro growth rate, soft agar colony formation, tumorigenicity in vivo, tumor latency period, and tumor size after 13 weeks are compared Figure 3 Soft agar analysis of CD1 nu/nu mouse revertant tumors: Comparison of colony forming ability for hybrids #01 and #18 in the presence and absence of G418. Each microcell hybrid line consists of cells that were passaged in vitro under G418 selection and CD1 nu/nu mouse derived subcutaneous tumor cells. Tumor cells passaged in vivo were absent for G418 selection. Hybrids #01 and #18 were selected because they failed to demonstrate colony formation in vitro, but developed tumors in some of the nude mice Characterization of hybrids by microsatellite analysis When a psv 2 neo-chromosome 22 heterokaryon integrates as a stable hybrid, it sometimes loses a portion of the chromosome. This loss of chromosomal material can sometimes be useful in functionally mapping which chromosome region(s) is most likely to contain our critical gene(s) of interest. If, for example, chromosome 22 contained a tumor suppressor gene and expression of this gene had an eect upon cell growth and tumorigenicity, then a portion of chromosome 22 would be expected to be retained in all hybrids that failed to grow in soft agar or in nude mice (provided of course that these phenotypes are aected by only one gene on chromosome 22).
To gain insight into which region(s) of the psv 2 neochromosome 22 co-segregate with the ability of the microcell hybrids to suppress tumor growth, 43 microsatellite repeat markers spanning all of chromosome 22q were tested to map allelic gain in the microcell hybrid lines. Eight of these microsatellite markers were useful for gain of polymorphism mapping among the microcell hybrid lines. Of those eight informative markers, only D22S429 was retained by all hybrids that suppressed colony formation and tumorigenic potential in nude mice ( Figure 5 ). Of the 18 microcell hybrids tested, 10 demonstrated a gain of polymorphism at all eight markers, and three of the 18 showed allelic gain at only the D22S429 marker. These data provide functional support for a tumor growth suppressor locus (loci) located between markers D22S301 and D22S304.
Discussion
Studies of cancer mutations and the pathways that they regulate have spearheaded much of our current understanding of tumorigenesis. Many of these critical somatic mutations were ®rst identi®ed as recurrent regions of LOH and/or cytogenetic abnormalities. In this study we used microcell transfer to identify a novel region on chromosome 22 likely to contain a tumor suppressor gene(s) important in ovarian cancer tumorigenesis. Microcell transfer of the psv 2 neo-chromosome 22 into the SKOv-3 ovarian cancer cell line abrogated soft agar colony formation, decreased cellular in vitro growth rate, and reduced tumorigenic growth in nude mice (Table 1) . Furthermore, reversion of two microcell hybrids to a more tumorigenic state associated with loss of G418 resistance (Figure 3) .
These results suggest that a gene or genes on chromosome 22 may contribute to a growth suppression phenotype. The most notable exception to this pattern were hybrids #03 and #11. We have thus far been unable to demonstrate why these hybrids failed to completely suppress the transformed phenotype. Both hybrids #03 and #11 behaved like the parental SKOv-3 line with respect to doubling times and the ability to form colonies in soft agar. However, hybrids #03 and #11 did not behave similarly in their ability to form subcutaneous tumors in CD1 nude mice (Table 1) . Such phenotypic disassociation between tumorigenicity in nude mice and soft agar colony formation is not, however, without precedent (Stanbridge and Wilkinson, 1978; Steck et al., 1995) . Indeed, the former group observed that the transformed phenotype of soft agar colony formation does not always correlate strongly with growth in nude mice and that there must be at least some divergence in the genetic mechanisms which control these phenotypes. It is possible that this disassociation between the ability to grow in soft agar, and the tumorigenic capability in nude mice may be indicative of the eects of multiple loci on chromosome 22. However, dierences in genetic background between the hybrids cannot be ruled out. Alternatively, the microcell fusion process may have resulted in the incorporation of chromosome 22 with an undetected deletion(s) or mutation(s) resulting in failure of these hybrids to fully complement the tumorigenic phenotype. While we cannot explain why microcell hybrids #03 and #11 failed to completely suppress the Figure 5 Gain of polymorphism analysis: A map of allelic gain among the microcell hybrid cell lines using informative chromosome 22 microsatellite markers. The gray dots indicated a gain of polymorphism suggesting regions of the chromosome where an additional chromosome 22 allele is present. The white dots represent regions where an allelic gain was not present suggesting regions which do not correlate with the ability to suppress tumor growth transformed phenotype, we can conclude, however, that the dierences in growth rate, anchorage-independent growth, and tumorigenicity displayed by the chromosome 22 hybrid cell lines were not the result of the microcell fusion procedure itself, nor were they simply due to the eects of clonal selection.
While most microcell transfers generally cause an altered phenotype through complementation, we cannot rule out the possibility that transfer of a normal chromosome 22 could be exerting its in¯uence on the phenotype of SKOv-3 cells through an increase in gene dosage for a critical growth regulatory gene. Regardless of the mechanism of growth suppression, this does not change the conclusion that the inhibition of tumorigenicity is exerted through the actions of a tumor suppressor gene.
Our next objective was to determine if any retained region(s) of chromosome 22 among the microcell hybrid clones correlated with the oncogenic suppression phenotype. Such information could be useful in localizing the critical region(s) containing a tumor suppressor locus. Among the 18 hybrids analysed, eight demonstrated partial psv 2 neo-chromosome 22 loss while also retaining oncogenic suppression. Three of these hybrids, #15, #16, and #17, retained only the D22S429 marker ( Figure 5 ). Nude mouse tumor growth curves for these microcell hybrids demonstrated complete failure to form tumors as compared to parental controls (Figure 2 ). These data suggest that the gene or genes driving this tumor growth suppression phenotype may localize to the chromosome region surrounding the D22S429 marker. This 30.6 cM region (Collins et al., 1995) surrounding D22S429 does not overlap with the critical region implicated by previous studies of LOH deletion mapping in ovarian cancer (22q13), and therefore suggests that a novel tumor suppressor locus (loci) may localize to this region (22q11-q12). Our data do not rule out the possibility that additional unrecognized regions of chromosome 22 may be retained among the microcell hybrids with suppressed growth and tumorigenicity (or lost in those hybrids that do not suppress). These data do, however, introduce the possibility that multiple regions of chromosome 22 may be involved in the progression of ovarian epithelial malignancies. Similar observations are reported in meningiomas where as many as six regions of chromosome 22 may contribute to tumor initiation and progression. These regions include the NF2 tumor suppressor locus (Kinzler and Vogelstein, 1993; Sanson et al., 1993; Ruttledge et al., 1994; Wellenreuther et al., 1995) , the SIS oncogene (Bolger et al., 1985; Smidt et al., 1990) , the MN1 gene (Buijs et al., 1995; Lekanne Deprez et al., 1995) , the BAM22 gene (Dumanski et al., 1987; Peyrard et al., 1994) , the SMARCB1 gene (Versteege et al., 1998) and a deletion region on chromosome 22q13.3 (Akagi et al., 1995) . While mutations in the NF2 gene are prevalent in several tumors of the nervous system, Engle®eld et al. (1994) report no NF2 mutations by SSCP analysis of 67 ovarian tumors. In contrast, the meningioma deletion region on chromosome 22q13.3 may share overlap with the LOH regions localized in several tumors including glioblastomas, colon cancers, and epithelial ovarian carcinomas (Akagi et al., 1995; Yana et al., 1995; Bryan et al., 1996) . The region between markers D22S301 and D22S304 that is functionally associated with suppression of SKOv-3 cell growth and tumorigenicity contains BAM22, MN1 and SMARCB1.
In summary, microcell fusion was carried out to determine if chromosome 22 could reduce the tumorigenic potential of the SKOv-3 malignant ovarian cancer cell line. The majority of the psv 2 neo-chromosome 22 microcell hybrids had an altered morphology, decreased in vitro cellular growth rate, abrogation of anchorage-independent growth, and substantially reduced tumorigenic capability in CD1 nude mice. Together these data provide the ®rst functional evidence that a tumor suppressor(s) contributing to ovarian cancer tumorigenesis exists on chromosome 22.
Materials and methods
Microcell mediated chromosome transfer
The SKOv-3 cell line (purchased from the American Type Culture Collection) was selected as the recipient cell line for the microcell fusion procedure. SKOv-3 cell line was derived from the ascites of an ovarian adenocarcinoma, and has a reported karyology of 32 ± 88 chromosomes with the following clonal structural abnormalities: t(1 : 13)(1p22;13q34) del(3)(p13:) del(6)(q23:) del(11)(q21:) del(12)(q22:) including 15 ± 19 unidenti®ed marker chromosomes (Buick et al., 1985) . The donor cell line, HA(22)9, was a generous gift provided by Dr Ann Killary (MD Anderson Cancer Center). This microcell fusion method has been described in detail by Killary and Fournier (1995) . In brief, the microcell mediated chromosome transfer protocol involves the creation of microcells, the fusion of microcells with tumor cells, and the selection and expansion of microcell hybrids.
The HA(22)9 donor cell line containing the selectable psv 2 neo gene was grown in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS) (Sigma) and 500 mg/ ml G418 (Gibco). When donor-cell plates reached 80 ± 90% con¯uence, they were trypsinized, pelleted, and resuspended in 2 ml of culture medium. Under sterile conditions, plastic bullets' containing the donor-cells were transferred to 150 mm tissue culture plates (four bullets per plate), and covered with 48 ml of DMEM/F12 medium. The donor cells were added in a dropwise manner onto the bullets (1 ml/2 bullets) and incubated 4 ± 6 h to permit adherence. Colcemid (0.06 mg/ml) was added and cells incubated for 48 h. The resulting microcells were then separated by high speed centrifugation (27 000 g) in the presence of cytochalasin B (10 mg/ml). The microcells containing single chromosomes or small groups of chrommosomes were then isolated by a series of ®ltration steps through polycarbonate ®lters (0.8, 0.5 and 0.3 mm) and added to a 70% con¯uent T25¯ask containing the recipient SKOv-3 cell line. These microcells were added in the presence of 200 mg/ml phytohemagglutinin P (PHA-P) (Difco Laboratories) in serum-free DMEM/F12. Microcells were left in the presence of 2 ml of PHA-P containing medium for precisely 10 min at 378C. The cells were then washed twice in medium without serum and treated with 1 ml of 45% PEG for exactly 60 s with a gentle rocking motion. The cells were then washed twice with serum-free media being careful to only let media roll gently over the cells. Medium supplemented with FBS but without G418 was then added to the cells and incubated for 48 h to permit stable incorporation of the fused chromosome. As a negative control, cells were exposed to PHA-P in the absence of microcells. Cells were then split into 10 T25¯asks and placed under G418 selection. Growth of cells was only observed in those cultures incubated with microcells. After 2 weeks of selection, 20 G418 resistant colonies were isolated from 20¯asks.
YAC modification and analysis
A homologous recombination approach using the polyethylene glycol (PEG) transformation method (Burgers and Percival, 1987) was used to retro®t the right arm of the YACs with the pRAN4 vector (Markie et al., 1993) containing the aminoglycoside phosphotransferase (neo) gene which confers resistance to neomycin (G418). The yeast transformants were selected for the desired phenotype (UraAde+Trp+) on synthetic dropout (SD) medium supplemented with 20 mg/L uracil (Sigma Co. St. Louis, MO, USA), 1 mg/ml 5-¯uoroorotic acid (ICN, Costa-Mesa, CA, USA), 20 mg/L each of tryptophan, isoleucine, lysine, and histidine.
Retro®tting was con®rmed by pulse ®eld gel electrophoresis (PFGE), Southern blotting and PCR. Brie¯y, agarose plugs of high-molecular-weight yeast DNA were prepared from single colonies of each selected transformant after overnight growth in selective SD medium, essentially as described (Mendez et al., 1991) . PFGE was carried out using a CHEF gel apparatus (BioRad, Richmond, CA, USA). DNA was transferred to Hybond-N membranes (Amersham, Arlingotn Heights, IL, USA) as suggested by the manufacturer. DNA probes were labeled with a-32 P-dCTP (Amersham, 6000 Ci/mmol), using an oligonucleotide random labeling kit (Boehringer Mannheim Co., Indianapolis, IN, USA). DNA hybridization and washes were performed at 658C. The neo gene probe was obtained by PCR ampli®cation of this gene from the plasmid pSV2-neo (Clontech, Palo Alto, CA, USA), using the neo gene primers listed: neo-F:CCAGAGTCCCGCTCAGAAGAACTC; neo-R:CTTGCTCCTGCCGAGAAAGTATCC.
Fusion of yeast spheroplasts to SKOv-3 cells
The neo-retro®tted YACs were fused to SKOv-3 cells by a modi®cation of previously described protocols for spheroplast fusion (Pachnis et al., 1990; Markie et al., 1993) . Yeast cells were grown in selective SD medium to a density of 1.5 ± 2.0610 7 and spheroplasted with 26 mg/ml of lyticase (ICN, cat. #155570). SKOv-3 cells at 70 ± 80% con¯uency were harvested by trypsinization and washed three times in serumfree RPMI 1640 medium (Gibco-BRL). In two separate experiments a total of 10 7 or 5610 7 SKOv-3 cells was pelleted in a 15 ml polystyrene tube, the medium was discarded, and 2610 8 or 1610 9 spheroplasted yeast cells (a 20-fold excess), suspended in STC buer (1 M Sorbitol, 10 mM Tris-HCl pH 7.5 and 10 mM CaCl 2 ), were layered on top and pelleted at 100 g for 6 min. The cell pellet was gently resuspended in 4 ml of 50% PEG-4000 solution (Boehringer Mannheim), 10 mM CaCl 2 , 75 mM HEPES, pH 7.4). After 120 s at room temperature, 20 ml of RPMI 1640 medium was added slowly, mixed gently by inversion and the cells were collected by centrifugation at 100 g for 4 min. The pellet was resuspended in complete medium and plated over 10 to 20 100-mm dishes. Twenty-four hours later plates were washed with phosphate-buered saline (PBS) to remove dead cells and yeast cells and fed with complete medium plus 600 mg/ml of geneticin (G418, Gibco-BRL). Plates that showed persistent yeast cell growth after 6 days were usually discarded. Cells were refed every 3 ± 4 days and discrete resistant colonies usually appeared after 14 ± 21 days. Due to the large number of colonies observed in some of the plates, which makes it dicult to accurately estimate the frequency of YAC transfer by scoring the number of individual G418-resistant (G418 r ) clones, colony formation was appraised by categorizing the plates according to the observed number and size of the G418 r colonies in each plate. After 3 weeks of selection in G418, plates were scored and colonies selected.
When possible ®ve to 10 individual colonies from plates of each category were isolated at day 21 post-selection using cloning cylinders, transferred to 96-well or 48-well plates and expanded for further analysis. In addition 1 ± 2 representative plates from each category were chosen after 25 days of G418 selection for trypsinization and counting using a ZM model Coulter counter (Coulter Co., Hialeah, FLA) .
A subset of representative expanded fusion cells derived from the following plate categories were chosen for assessment of the integrity of the transferred YAC DNA. For PCR analyses DNA was isolated from 1 ± 10610 3 cells using the PUREGENE TM DNA isolation kit (Gentra Systems, Inc. Minneapolis, MN, USA) following the protocol supplied by the manufacturer.
Anchorage-dependent growth rate
Growth rate was determined by plating 10 000 cells into each well of a 24-well plate then trypsinizing and counting cells every 24 h over a 3 day period. The cells were counted both in a hemocytometer with 0.4% trypan blue staining and with a Coulter counter (Model Z3). Measurement of culture growth was performed in triplicate for each cell line. Doubling times were calculated by determining growth rate during the period of linear growth using the equation below where T is the time between observations and N is the number of cells counted:
Anchorage-independent growth One ml of 0.3%`top' agar containing 2610 5 cells was placed over 1 ml of 0.6%`bottom' agar in 35610 mm culture dishes with 2 mm grids (Nunc) at 428C. The 0.6%`bottom' agar mixture contained 25% agar (2.4%), 10% FBS (Sigma) and 65% fully supplemented McCoy's 5A media. The 0.3%`top' agar contained a 1 : 1 ratio of fully supplemented McCoy's 5A media and the 0.6%`bottom' agar mixture. Each experimental condition was carried out in triplicate. Cells were incubated at 378C for 2 weeks before counting colonies. Colonies with greater than 30 cells were scored.
Analyses in nude mice
Six week old CD1 nu/nu mice (Charles River) were injected subcutaneously into one¯ank with 1610 7 cells in 0.1 ml with sterile PBS. Five to seven mice were injected per group. The latency period was determined as the point in time when a subcutaneous tumor became committed to a pattern of tumor growth for each nude mouse. Tumor growth was monitored twice a week over a 20 ± 25 week period by measuring tumor length, width and height. Upon sacri®ce, excised tumors were plated for 2 ± 3 days and analysed for dierences in anchorage independent growth (see text).
PCR analysis and DNA microsatellite polymorphic markers DNA was extracted from cell lines as described in Sambrook et al. (1989) . Eight of 43 microsatellite markers, selected from the Genome Data Base and purchased from Research Genetics (Huntsville, AL, USA), were used to genotype the neomycin-resistant hybrid cell lines. These markers include: D22S156, D22S258, D22S264, D22S270, D22S273, D22S275, D22S278, D22S283, D22S294, D22S300, D22S301, D22S303, D22S304, D22S315, D22S420, D22S421, D22S426, D22S429, D22S431, D22S444, D22S445, D22S446, D22S450, D22S526, D22S683, D22S684, D22S685, D22S689, D22S690, D22S694, D22S922, D22S928, D22S1141, D22S1149, D22S1153, D22S1154, D22S1160, D22S1161, D22S1167, D22S1169, D22S1170, F8VWFP, and TOPIP2F (Collins et al., 1995) . Only D22S301, D22S304, D22S429, D22S444, D22S446, D22S450, D22S922, and D22S928 were informative and were used for further analysis. PCR ampli®cation incorporating 33 [P]dATP was carried out as previously described (Kruzelock et al., 1997). The distance between markers was determined Oncogene Chromosome 22 microcell transfer RP Kruzelock et al from a published genetic map of chromosome 22 (Collins et al., 1995) .
Cytogenetic analyses
Metaphase spreads were obtained by treating a 70 ± 80% con¯uent unsynchronized monolayer of SKOv-3 cells with 0.8 mg/ml colcemid for 1 h and harvesting by standard methods (Dracopoli et al., 1997) . G11 banding was performed as described by Aldahe (1977) . Chromosome 22 in situ hybridization and detection were performed as described in the manufacturer's protocol (Oncor) for their digoxigenin-labeled chromosome 22 probe (cotasome 22).
Counterstaining was performed using propidium iodide in an antifade buer provided by the manufacturer. At least 25 metaphases were scored for each cell line for both the G11 banding and the chromosome`painting' slides.
